<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05118711</url>
  </required_header>
  <id_info>
    <org_study_id>EKNZ 2021-01039</org_study_id>
    <nct_id>NCT05118711</nct_id>
  </id_info>
  <brief_title>Sequelae of COVID-19 With Focus on Exercise Capacity and Underlying Mechanisms</brief_title>
  <acronym>COR-PHYS</acronym>
  <official_title>COVID-19 Severity, Long-term Consequences for Exercise Capacity and Link to Associated Mechanisms</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Arno Schmidt-Trucksäss</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Basel</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The project is designed as a cross-sectional study and aims to examine middle- to long-term&#xD;
      consequences of coronavirus disease 2019 (COVID-19) for selected bio-behavioural parameters&#xD;
      while taking the disease course severity into account.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 2022</start_date>
  <completion_date type="Anticipated">May 2024</completion_date>
  <primary_completion_date type="Anticipated">May 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Cardiorespiratory fitness (as % of predicted V̇O2max)</measure>
    <time_frame>1.5 hours after inclusion in study</time_frame>
    <description>Measured during cardiopulmonary exercise testing on a cycle ergometer.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Forced expiratory volume in 1 s (as % of predicted)</measure>
    <time_frame>1.5 hours after inclusion in study</time_frame>
    <description>Measured during bodyplethysmography.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Forced vital capacity (as % of predicted)</measure>
    <time_frame>1.5 hours after inclusion in study</time_frame>
    <description>Measured during bodyplethysmography.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total lung capacity (as % of predicted)</measure>
    <time_frame>1.5 hours after inclusion in study</time_frame>
    <description>Measured during bodyplethysmography.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diffusion capacity of the lungs (as % of predicted)</measure>
    <time_frame>1.5 hours after inclusion in study</time_frame>
    <description>Measured during bodyplethysmography.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Muscle oxygenation at peak exercise (in %)</measure>
    <time_frame>1.5 hours after inclusion in study</time_frame>
    <description>Measured using near-infrared spectroscopy during cardiopulmonary exercise testing on a cycle ergometer.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac output at peak exercise (in mL)</measure>
    <time_frame>1.5 hours after inclusion in study</time_frame>
    <description>Measured non-invasive using the PhysioFlow device during cardiopulmonary exercise testing on a cycle ergometer.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Handgrip strength (in N)</measure>
    <time_frame>1 hour after inclusion in study</time_frame>
    <description>Measured by a handheld dynamometer.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Handgrip rate of force development (in N/s)</measure>
    <time_frame>1 hour after inclusion in study</time_frame>
    <description>Measured by a handheld dynamometer.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Macrovascular flow-mediated dilation at rest (in %)</measure>
    <time_frame>0.5 hours after inclusion in study</time_frame>
    <description>Measured by ultrasound.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Microvascular flow-mediated dilation at rest (in %)</measure>
    <time_frame>2 to 14 days after inclusion in study</time_frame>
    <description>Measured by retinal vessel analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fatigue Assessment Scale (FAS) score</measure>
    <time_frame>2 to 14 days after inclusion in study</time_frame>
    <description>Scores range from 5 to 50 with higher scores indicating more severe fatigue.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Score of depression, anxiety, and stress questionnaire (DASS21)</measure>
    <time_frame>2 to 14 days after inclusion in study</time_frame>
    <description>Scores range from 0 to 63 with higher scores indicating worse mental health.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health distance</measure>
    <time_frame>Calculated during statistical analysis</time_frame>
    <description>The statistical (Mahalanobis) distance (health distance) is a composite measure of various health biomarkers</description>
  </secondary_outcome>
  <number_of_groups>7</number_of_groups>
  <enrollment type="Anticipated">450</enrollment>
  <condition>Moderate COVID-19</condition>
  <condition>Severe COVID-19</condition>
  <condition>Controls</condition>
  <arm_group>
    <arm_group_label>Moderate COVID-19 (12 months post-infection)</arm_group_label>
    <description>Individuals with a positive severe acute respiratory syndrome-novel coronavirus-2 (SARS-nCOV-2) antigen-/polymerase chain reaction (PCR) test within the last 12 months that required hospitalisation in a normal ward. Symptoms typically worsened within a period of 5 to 10 days leading to e.g., prolonged fever, feeling of sickness and/or shortness of breath.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Severe COVID-19 (12 months post-infection)</arm_group_label>
    <description>Individuals with a positive SARS-nCOV-2 antigen-/PCR test within the last 12 months that required hospitalisation in an intensive care ward. Additionally, patients hospitalised in a normal ward but requiring nasal high flow therapy or &gt;4 L/min of oxygen administration.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Moderate COVID-19 (18 months post-infection)</arm_group_label>
    <description>Individuals with a positive SARS-nCOV-2 antigen-/PCR test within the last 18 months that required hospitalisation in a normal ward. Symptoms typically worsened within a period of 5 to 10 days leading to e.g., prolonged fever, feeling of sickness and/or shortness of breath.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Severe COVID-19 (18 months post-infection)</arm_group_label>
    <description>Individuals with a positive SARS-nCOV-2 antigen-/PCR test within the last 18 months that required hospitalisation in an intensive care ward. Additionally, patients hospitalised in a normal ward but requiring nasal high flow therapy or &gt;4 L/min of oxygen administration.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Moderate COVID-19 (24 months post-infection)</arm_group_label>
    <description>Individuals with a positive SARS-nCOV-2 antigen-/PCR test within the last 24 months that required hospitalisation in a normal ward. Symptoms typically worsened within a period of 5 to 10 days leading to e.g., prolonged fever, feeling of sickness and/or shortness of breath.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Severe COVID-19 (24 months post-infection)</arm_group_label>
    <description>Individuals with a positive SARS-nCOV-2 antigen-/PCR test within the last 24 months that required hospitalisation in an intensive care ward. Additionally, patients hospitalised in a normal ward but requiring nasal high flow therapy or &gt;4 L/min of oxygen administration.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <description>Age- and sex-matched (frequency matching), fully vaccinated individuals with no history of SARS-nCOV-2 infection. The latter will be verified via virological blood biomarkers wherever possible.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Cardiorespiratory fitness</intervention_name>
    <description>Cardiopulmonary exercise testing</description>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_label>Moderate COVID-19 (12 months post-infection)</arm_group_label>
    <arm_group_label>Moderate COVID-19 (18 months post-infection)</arm_group_label>
    <arm_group_label>Moderate COVID-19 (24 months post-infection)</arm_group_label>
    <arm_group_label>Severe COVID-19 (12 months post-infection)</arm_group_label>
    <arm_group_label>Severe COVID-19 (18 months post-infection)</arm_group_label>
    <arm_group_label>Severe COVID-19 (24 months post-infection)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Lung function</intervention_name>
    <description>Body plethysmography</description>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_label>Moderate COVID-19 (12 months post-infection)</arm_group_label>
    <arm_group_label>Moderate COVID-19 (18 months post-infection)</arm_group_label>
    <arm_group_label>Moderate COVID-19 (24 months post-infection)</arm_group_label>
    <arm_group_label>Severe COVID-19 (12 months post-infection)</arm_group_label>
    <arm_group_label>Severe COVID-19 (18 months post-infection)</arm_group_label>
    <arm_group_label>Severe COVID-19 (24 months post-infection)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Muscular strength and balance tests</intervention_name>
    <description>Handgrip strength test, mid-thigh pull test and standing balance test in static tandem stance</description>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_label>Moderate COVID-19 (12 months post-infection)</arm_group_label>
    <arm_group_label>Moderate COVID-19 (18 months post-infection)</arm_group_label>
    <arm_group_label>Moderate COVID-19 (24 months post-infection)</arm_group_label>
    <arm_group_label>Severe COVID-19 (12 months post-infection)</arm_group_label>
    <arm_group_label>Severe COVID-19 (18 months post-infection)</arm_group_label>
    <arm_group_label>Severe COVID-19 (24 months post-infection)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Micro- and macrovascular endothelial function and cardiac function</intervention_name>
    <description>Measurement of flow-mediated dilation, static and dynamic retinal vessel analysis, echocardiography</description>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_label>Moderate COVID-19 (12 months post-infection)</arm_group_label>
    <arm_group_label>Moderate COVID-19 (18 months post-infection)</arm_group_label>
    <arm_group_label>Moderate COVID-19 (24 months post-infection)</arm_group_label>
    <arm_group_label>Severe COVID-19 (12 months post-infection)</arm_group_label>
    <arm_group_label>Severe COVID-19 (18 months post-infection)</arm_group_label>
    <arm_group_label>Severe COVID-19 (24 months post-infection)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Blood sampling and analysis</intervention_name>
    <description>Blood sampling by venepuncture</description>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_label>Moderate COVID-19 (12 months post-infection)</arm_group_label>
    <arm_group_label>Moderate COVID-19 (18 months post-infection)</arm_group_label>
    <arm_group_label>Moderate COVID-19 (24 months post-infection)</arm_group_label>
    <arm_group_label>Severe COVID-19 (12 months post-infection)</arm_group_label>
    <arm_group_label>Severe COVID-19 (18 months post-infection)</arm_group_label>
    <arm_group_label>Severe COVID-19 (24 months post-infection)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Physical activity</intervention_name>
    <description>Physical activity surveillance using accelerometers</description>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_label>Moderate COVID-19 (12 months post-infection)</arm_group_label>
    <arm_group_label>Moderate COVID-19 (18 months post-infection)</arm_group_label>
    <arm_group_label>Moderate COVID-19 (24 months post-infection)</arm_group_label>
    <arm_group_label>Severe COVID-19 (12 months post-infection)</arm_group_label>
    <arm_group_label>Severe COVID-19 (18 months post-infection)</arm_group_label>
    <arm_group_label>Severe COVID-19 (24 months post-infection)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Questionnaires</intervention_name>
    <description>Global physical activity questionnaire (GPAQ), short-form 8 health survey (SF-8), barriers to physical activity, fatigue assessment scale (FAS), modified medical research council dyspnea scale (mMRC), depression, anxiety, and stress scale (DASS21), post-COVID-19 syndrome symptoms</description>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_label>Moderate COVID-19 (12 months post-infection)</arm_group_label>
    <arm_group_label>Moderate COVID-19 (18 months post-infection)</arm_group_label>
    <arm_group_label>Moderate COVID-19 (24 months post-infection)</arm_group_label>
    <arm_group_label>Severe COVID-19 (12 months post-infection)</arm_group_label>
    <arm_group_label>Severe COVID-19 (18 months post-infection)</arm_group_label>
    <arm_group_label>Severe COVID-19 (24 months post-infection)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Body composition</intervention_name>
    <description>Dual-energy x-ray absorptiometry (DXA)</description>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_label>Moderate COVID-19 (12 months post-infection)</arm_group_label>
    <arm_group_label>Moderate COVID-19 (18 months post-infection)</arm_group_label>
    <arm_group_label>Moderate COVID-19 (24 months post-infection)</arm_group_label>
    <arm_group_label>Severe COVID-19 (12 months post-infection)</arm_group_label>
    <arm_group_label>Severe COVID-19 (18 months post-infection)</arm_group_label>
    <arm_group_label>Severe COVID-19 (24 months post-infection)</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood samples (total volume 15.7 mL) will be collected by venipuncture of the cubital fossa,&#xD;
      are subsequently centrifuged and the plasma aliquots are frozen at -80°C.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients recovering from moderate or severe COVID-19 and fully vaccinated controls with no&#xD;
        history of COVID-19.&#xD;
&#xD;
        Recruitment of patients will be done via the University Hospital of Basel, Switzerland, the&#xD;
        Clinic Barmelweid, Barmelweid, Switzerland, and Cantonal Hospital Olten,Olten, Switzerland.&#xD;
        Participants for the control group will be recruited prospectively thru the COVID-19&#xD;
        testing center at the University Hospital of Basel (individuals that received a negative&#xD;
        SARS-nCOV-2 test result), unaddressed letters distributed in the Basel-Stadt area,&#xD;
        newspaper, internet-based media, and word-of-mouth. Recruitment will continue until the&#xD;
        number of valid datasets corresponds to the calculated sample size.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  tested positive for SARS-nCOV-2 using antigen- or PCR tests within the last 24 months&#xD;
&#xD;
          -  previous hospitalization due to COVID-19&#xD;
&#xD;
          -  fully vaccinated (only for controls)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  inability to follow the study procedures (e.g. due to language barriers, psychological&#xD;
             disorders, dementia, etc.),&#xD;
&#xD;
          -  known pregnancy or lactating women,&#xD;
&#xD;
          -  presence of any contraindications for exercising until maximum exhaustion, including&#xD;
             insufficient blood pressure control (systolic &gt;170 mmHg, diastolic &gt;100 mmHg), ongoing&#xD;
             cancer treatment, unstable angina pectoris, uncontrolled bradyarrhythmia or&#xD;
             tachyarrhythmia, severe uncorrected valvular heart disease, clinically relevant acute&#xD;
             infection, any form of musculoskeletal injury,&#xD;
&#xD;
          -  participating in any interventional clinical trial within the last four weeks,&#xD;
&#xD;
          -  previous participation in the current study&#xD;
&#xD;
          -  history of COVID-19 (only for controls)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Arno Schmidt-Trucksäss, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Sport, Exercise and Health, University of Basel, Basel, Switzerland</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Arno Schmidt-Trucksäss, Prof.</last_name>
    <phone>+41 61 207 47 40</phone>
    <email>arno.schmidt-trucksaess@unibas.ch</email>
  </overall_contact>
  <location>
    <facility>
      <name>Division of Sports and Exercise Medicine, Department of Sport, Exercise and Health, University of Basel</name>
      <address>
        <city>Basel</city>
        <state>BS</state>
        <zip>4052</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 8, 2021</study_first_submitted>
  <study_first_submitted_qc>November 11, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 12, 2021</study_first_posted>
  <last_update_submitted>November 11, 2021</last_update_submitted>
  <last_update_submitted_qc>November 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Basel</investigator_affiliation>
    <investigator_full_name>Arno Schmidt-Trucksäss</investigator_full_name>
    <investigator_title>Sponsor-Investigator and Head of Rehabilitative and Regenerative Sports Medicine, Department of Sport, Exercise and Health</investigator_title>
  </responsible_party>
  <keyword>SARS-nCOV-2</keyword>
  <keyword>Coronavirus</keyword>
  <keyword>Sequelae</keyword>
  <keyword>Exercise intolerance</keyword>
  <keyword>Cardiopulmonary exercise testing</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

